Tuesday, August 26, 2014 10:33:44 AM
Today that same company has over 650,000,000 shares outstanding and has stated that they have spoken to the Converters and will only issue 100,000,000 million shares per quarter.. That 100 Mil. is almost 8 times what was the total shares outstanding at that time,, just 2 years ago.... Thru dilution ACGX has diluted the interest of current shareholders over 80 Times and at the rate they are going it will be 100 Times before year end..
Since insiders control thru the Preferred as long as the have one share of preferred they control and as before with a stroke of the pen may change the conversion rate at will.. Now I realize that some consider this bashing but facts are hard to dispute in any court of reference.. hank..
Recent ACGX News
- Alliance Creative Group (ACGX) Releases 2023 Annual Financial and Disclosure Report - PeopleVine's revenue increased by 100% in 2023 • InvestorsHub NewsWire • 04/01/2024 12:00:00 PM
- Alliance Creative Group (ACGX) Reports Third Quarter of 2023 Financials • InvestorsHub NewsWire • 11/15/2023 01:00:00 PM
- Alliance Creative Group (ACGX) Reports Second Quarter of 2023 Financials • InvestorsHub NewsWire • 08/14/2023 08:30:00 PM
- Alliance Creative Group (ACGX) Becomes an Equity Partner of the Coastal Spritz Brand • InvestorsHub NewsWire • 06/13/2023 12:00:00 PM
- Alliance Creative Group (ACGX) Reports First Quarter of 2023 Financials with Over $4,000,000 in assets • InvestorsHub NewsWire • 05/15/2023 12:30:00 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM